← Back to all trials
Active Not Recruiting
NCT01352429
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
Conditions: Prostate Adenocarcinoma
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 303
Sponsor: Abramson Cancer Center at Penn Medicine
Location: Walter Reed National Military Medical Center Bethesda Maryland
Summary
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or Intensity Modulated Radiation Therapy (IMRT). The investigators propose to employ a hypofractionated strategy with our image guided treatment to further improve cancer control and decrease toxicity.
Eligibility Criteria
Inclusion Criteria
* Histologically confirmed prostate adenocarcinoma within 365 days of registration.
* Clinical stages T1a-T2c N0 M0 (AJCC Criteria 6th Ed). For any suspicious pelvic lymph node \> 1.5cm (as exhibited on pelvic imaging), biopsy of the lymph node is suggested.
* Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range 2-7. Biopsy with \> 6 cores is strongly recommended. (The highest Gleason Score in any core reported on the pathology report will be used for determining inclusion.)
* PSA values \
Source: ClinicalTrials.gov (NCT01352429). StuddyBuddy aggregates publicly available trial information.
